Abstract:Background Microtubule-associated proteins (MAPs) have been considered to play significant roles in the tumor evolution of non-small cell lung cancer (NSCLC). Nevertheless, mRNA transcription levels and prognostic value of distinct MAPs in patients with NSCLC remain to be clarified. Methods In this study, the Oncomine database, Gene Expression Profiling Interactive Analysis (GEPIA) database, and Human Protein Atlas were utilized to analyze the relationship between mRNA/protein expression of different MAPs and clinical characteristics in NSCLC patients, including tumor type and pathological stage. The correlation between the transcription level of MAPs and overall survival (OS) of NSCLC patients was analyzed by Kaplan-Meier plotter. Besides, 50 frequently altered neighbor genes of the MAPs were screened out, and a network has been constructed via the cBioPortal and Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) dataset. Meanwhile, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis on the expression data of MAPs and their 50 frequently altered neighbor genes in NSCLC tissues. Furthermore, The Cancer Immunome Atlas (TCIA) was utilized to analyze the relationship between MAP expression and the response to immunotherapy. Finally, we used reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to verify the expression of MAPs in 20 patients with NSCLC. Results The present study discovered that the mRNA transcription levels of MAP7/7D2 were enriched in NSCLC tissues, while those of the MAP2/4/6/7D3 were lower in NSCLC specimens than those in control specimens. The mRNA transcription level of MAP6 was significantly associated with the advanced stage of NSCLC. Besides, survival analysis indicated that higher mRNA expressions of MAP2/4/6/7/7D3 were correlated considerably with favorable OS of NSCLC patients, whereas increased mRNA expression levels of MAP1A/1S were associated with poor OS. Moreover, the expression of MAP1A/1B/1S/4/6/7D1/7D3 was significantly correlated with immunophenoscore (IPS) in NSCLC patients. Conclusions Our analysis indicated that MAP1A/1S could serve as potential personalized therapeutic targets for patients with NSCLC, and the enriched MAP2/4/6/7/7D3 expression could serve as a biomarker for favorable prognosis in NSCLC. Besides, the expression of MAP1A/1B/1S/4/6/7D1/7D3 was closely related to the response to immunotherapy. Taken together, MAP expression has potential application value in the clinical treatment and prognosis assessment of NSCLC patients, and further verifiable experiments can be conducted to verify our results.

MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial–mesenchymal transition in lung adenocarcinoma

MAPK4 Silencing in Gastric Cancer Drives Liver Metastasis by Positive Feedback Between Cancer Cells and Macrophages.

Prognostic Significance and Molecular Mechanism of ATP-Binding Cassette Subfamily C Member 4 in Resistance to Neoadjuvant Radiotherapy of Locally Advanced Rectal Carcinoma

MicroRNA-147b Promotes Lung Adenocarcinoma Cell Aggressiveness Through Negatively Regulating Microfibril-Associated Glycoprotein 4 (MFAP4) and Affects Prognosis of Lung Adenocarcinoma Patients.

MAPK4 Overexpression Promotes Tumor Progression Via Noncanonical Activation of AKT/mTOR Signaling

MAPK4 facilitates angiogenesis by inhibiting the ERK pathway in non-small cell lung cancer

MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage

Overcoming radioresistance of breast cancer cells with MAP4K4 inhibitors

Prognostic Value of GIMAP4 and Its Role in Promoting Immune Cell Infiltration into Tumor Microenvironment of Lung Adenocarcinoma

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

ADAMTS4 exacerbates lung cancer progression via regulating c-Myc protein stability and activating MAPK signaling pathway

Expression of MAP4K4 in Bladder Cancer and Its Biological Effect on Human Bladder Cancer T24 Cells

A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic intervention

LMO4 is a Prognostic Marker Involved in Cell Migration and Invasion in Non-Small-cell Lung Cancer.

MCM4 acts as a biomarker for LUAD prognosis

Considerations on the implementation of MAP4K4 inhibitors as cancer treatment

TEAD4 Exerts Pro-Metastatic Effects and is Negatively Regulated by Mir6839-3P in Lung Adenocarcinoma Progression

MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling

Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9

LAPTM4B is a Novel Diagnostic and Prognostic Marker for Lung Adenocarcinoma and Associated with Mutant EGFR

MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway